GlassScriptPhysician profile
Mjames Lenhard
NPI 1245218148
$49,199.74
in general payments reported to CMS, 2019-2025
19 companies · $761 in 2025
The $761 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $12K · 2021: $8,455 · 2022: $6,177 · 2023: $742 · 2024: $8,299 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,713 · Food and Beverage: $928 · Travel and Lodging: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,713.00 |
| Food and Beverage | $928.41 |
| Travel and Lodging | $160.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22,878.97 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $15,339.91 | 2019-2020 | |
| Lilly USA, LLC | $6,793.02 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $3,329.85 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $274.11 | 2021-2023 | |
| Novo Nordisk INC | $98.63 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $93.66 | 2019-2020 | |
| Mannkind Corporation | $79.20 | 2020 | |
| Abbott Laboratories | $64.39 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $54.35 | 2019 | |
| Shire North American Group INC | $44.69 | 2019 | |
| Amgen INC. | $31.08 | 2020 | |
| Medtronic, INC. | $24.07 | 2024 | Minimed 780g |
| Medtronic Minimed, INC. | $23.31 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.83 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $19.85 | 2019 | |
| Horizon Therapeutics Plc | $15.49 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mjames Lenhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.